A randomized, double-blind, placebo-controlled, dose-escalation study of adefovir dipivoxil, an oral prodrug of adefovir, was conducted in 36 human immunodeficiency virus (HIV) -infected subjects to evaluate its anti-HIV activity, safety, and pharmacokinetics. Subjects received placebo or one of three dosages of adefovir dipivoxil daily for 14 days. Median decreases in serum p24 antigen of 31% (P Å .02), 25% (P Å .31), and 30% (P Å .01) occurred in each drug-treated group, respectively, compared with an increase of 17% in the placebo group. Median decreases in serum HIV RNA of 0.4 -0.6 log 10 copies/mL occurred in the drug-treated groups (P Å .03), compared with no change in the placebo group. Gastrointestinal complaints and reversible liver transaminase elevations were the most frequently noted adverse events. Decreases in serum free carnitine occurred in each drug-treated group during treatment. After 14 days of dosing, adefovir dipivoxil demonstrated anti-HIV activity and was best tolerated at the lowest dosage studied, 125 mg daily.
The acyclic adenine phosphonate compound, 9-(2-phosphowith advanced HIV infection (n Å 8, median CD4 cell count, 42/mm 3 ) who received 1 mg/kg/day adefovir, the median p24 nylmethoxyethyl)adenine (adefovir), has demonstrated a broad spectrum of antiviral activity in both in vitro and animal models antigen concentration decreased from 150 to 76 pg/mL after 4 weeks of treatment [10] . In another trial in which subjects [1, 2] . Activity has been demonstrated against several RNA and DNA viruses, including human immunodeficiency virus received 1 mg/kg/day adefovir (n Å 10, mean CD4 cell count, 200/mm 3 ), the mean p24 antigen concentration decreased from (HIV) types 1 and 2, herpes simplex virus types 1 and 2, human herpesvirus 6, human cytomegalovirus, Epstein-Barr virus, and 209 to 103 pg/mL after 6 weeks of treatment [11] . Adefovir, however, demonstrated poor bioavailability when hepatitis B virus [3 -6] . The ED 50 of adefovir for inhibition of HIV-1 ranges from 0.006 to 7.0 mM depending on the cell administered orally as a solution to 5 HIV-infected subjects [12] . The oral bioavailability at 3.0 mg/kg/dose was õ12% (n culture system and assay type used [7, 8] . The active intracellular metabolite, adefovir diphosphate, an inhibitor of reverse Å 5) on the basis of serum levels [12] and was consistent with the degree of bioavailability observed in several animal species transcriptase, persists in cells, with a half-life ranging from 16 to 18 h [9] . in preclinical studies [13] . The low oral bioavailability of adefovir was attributed to the Previously, adefovir has been administered intravenously to patients with HIV infection in two clinical trials. In patients charged nature of the phosphonate group at physiologic pH, which may limit intestinal cellular uptake [14] . Therefore, to improve bioavailability, the bis-pivaloyloxymethyl ester of adefovir was synthesized to mask the negative charges of the plex-dissociated p24 antigen concentration of at least 50 pg/mL at the time of screening. To be eligible, at the time of screening, subjects must have had hepatic transaminases (aspartate aminotransferase and alanine aminotransferase) £100 IU/L (normal: £35 IU/L); lipase £260 IU/L (normal: £200 IU/L); an absolute neutrophil count of §1000/mm 3 ; and preserved coagulation function. Subjects were excluded if they were pregnant or lactating, undergoing parenteral treatment for an active serious infection, or lactose-intolerant. Subjects were allowed to continue approved prophylaxis for Pneumocystis carinii pneumonia. All subjects discontinued antiretroviral therapy at least 2 weeks prior to receiving Figure 1 . Structures of adefovir and adefovir dipivoxil. Arrows the first dose of adefovir dipivoxil. Nephrotoxic agents, systemic denote positions of pivaloyloxymethyl groups.
azoles, and rifamycins were contraindicated. Study drug. Each subject received 14 consecutive days of adefovir dipivoxil or identical-appearing lactose-containing placebo tablets. Adefovir dipivoxil tablets contained 125 mg each of active 500 mg of adefovir dipivoxil were given as a tablet to 10 HIVdrug. Drug was administered every 24 h at Ç9 A.M. following infected people, mean bioavailability was found to be Ç33% consumption of breakfast.
greater when administered after a meal (41.2% { 13%) than 
Methods
h after dosing on day 1 and day 14 (last day of dosing) for determiStudy design. This study was a 14-day randomized, doublenation of pharmacokinetic parameters. Urine samples were obblind, placebo-controlled, dose-escalation study of three dose tiers tained over the intervals 0-4, 4-8, 8-12, and 12-24 h following of adefovir dipivoxil: 125 mg, 250 mg, and 500 mg daily. Within dosing on days 1 and 14. Adefovir concentrations were quantified each tier of 12 subjects, 9 were randomly assigned to receive in serum and urine by a validated reverse-phase ion-pair highadefovir dipivoxil and 3 to receive placebo. The study was deperformance liquid chromatography procedure with fluorescent designed so that enrollment into the next sequential tier could occur rivatization [12] . Both procedures involved sample preparation only after all subjects in the previous tier had been observed for by use of strong anion-exchange solid-phase extraction columns at least 1 week after the completion of dosing. All subjects were (Whatman; VWR Laboratory Supply, San Francisco analysis and only the dose groups of adefovir dipivoxil were tration (C max ), the time to C max (T max ), AUC extrapolated to infinity, compared, no significant dose-dependent effect was seen.
and the half-life of the terminal elimination phase (t 1/2 ). For the All study groups had a rise in mean CD4 cell count; however, 250-mg and 500-mg dose groups, oral bioavailability was estithere was no significant difference between the change in the mated by comparing the serum AUC data obtained following oral placebo group and with the changes seen in the adefovir dipiadministration with the serum AUC data obtained following intravenous administration of adefovir in previous clinical trials [12] .
voxil -treated groups (data not shown).
For the 125-mg dose group, mean bioavailability was calculated abdominal discomfort (19%), and eructation or flatulence (19%).
Resulting P values were adjusted for multiple comparisons with
The frequency and severity of gastrointestinal events were dose- During dosing, 5 subjects in the 250-mg dose group and 4
Differences between day 1 and day 14 pharmacokinetic paramesubjects in the 500-mg group experienced reversible elevations ters within a given dose group were evaluated by using paired t of hepatic transaminases. These increases were graded as mild test analyses. Differences between dose groups were evaluated by (grade I: 40 -150 IU/L) or moderate (grade II: 151 -300 IU/ using unpaired t test analyses, which were not corrected for multi-L). In all subjects, transaminase levels returned to baseline ple groups.
within 2 weeks following discontinuation of therapy. Only two of the elevations were of grade II severity (table 2) . One subject in the 500-mg group, with a history of asympResults tomatic hyperlipasemia (400 -1137 IU/L) prior to study entry, was noted to have serum lipase concentrations between 1000 Study subjects. Thirty-six subjects entered and completed the study. Patient demographic data are shown in table 1. The and 1309 during the 14 days of drug therapy. He had no symptoms suggestive of pancreatitis. median age in each dose group ranged from 33 to 36 years. There was a predominance of males in all but the 250-mg One subject in the 500-mg group, with a history of both atrial fibrillation and presumed Gilbert's syndrome (bilirubin, dose group. Although there were differences between groups at study entry for median CD4 cell count, p24 antigen concen-1.4 mg/dL at baseline), reported nausea, decreased appetite, and intermittent vomiting while receiving drug. During the last tration, and HIV RNA concentration, these differences did not reach statistical significance. About two-thirds of the subjects day of drug administration, he experienced a 6-h episode of asymptomatic atrial fibrillation that resolved spontaneously. At had a history of antiretroviral use.
Antiviral activity. At day 15, significant median decreases the 1-week follow-up visit he was noted to have an elevated bilirubin measurement of 2.6 mg/dL, which decreased to 1.8 in serum p24 antigen of 31% (P Å .02) and 30% (P Å .01) occurred in the 125-mg and 500-mg groups, respectively, commg/dL 10 days later. One subject in the 125-mg dose group, with a history of pared with an increase of 17% in the placebo group (figure 2). Although of similar magnitude, the median decrease (25%) in untreated hyperglycemia (blood glucose, ú300 mg/dL and elevated hemoglobin A 1 C) and a baseline blood glucose level of the 250-mg group was not statistically significant (P Å .31).
At day 14, the median log 10 difference in HIV RNA PCR 211 mg/dL, was noted to have blood glucose concentrations in the range of 300 -600 mg/dL at 1 week and 4 weeks followresult was not significantly different among the groups by nonparametric analysis of variance: placebo Å 00.1 log 10 U/mL; ing the completion of drug administration. These findings were consistent with untreated type II diabetes mellitus. 125 mg Å 00.4 log 10 U/mL; 250 mg Å 00.6 log 10 U/mL; / 9d2f$$au38 06-24-97 21:34:00 jinfa UC: J Infect At baseline, all subjects' total and free serum carnitine levels below the normal range during the 14-day dosing period. Serum carnitine levels returned toward baseline after discontinuation were within the normal range (free: 2.3 -7.0 mmol/dL; total: 2.6 -8.1 mmol/dL). After 14 days of dosing (day 15), there of study drug dosing. At 1 week following completion of study drug administration (day 21), only 2 subjects (1 in each of the were dose-related decreases in free and total carnitine levels in the adefovir dipivoxil -treated groups. At day 15, in the 125-2 highest dose groups) had a carnitine level below the normal range; carnitine levels in the adefovir dipivoxil -treated groups mg group, the median decrease in serum free carnitine was 12% (P Å .02), compared with a median increase in the placebo were not significantly different from those in the placebo group. No study subject experienced symptoms suggestive of a carnigroup of 6% (figure 3). Despite the median decrease in the 125-mg dose group, no subject in this group had free (or total) tine deficiency syndrome, such as myopathy or encephalopathy.
Pharmacokinetics. Adefovir serum concentration curves carnitine levels that fell below the normal range. The median serum free carnitine reductions in the 250-mg and 500-mg for days 1 and day 14, normalized by subject weight, are shown in figure 4 . Mean adefovir C max values in the 125-mg and 250-groups at day 15 were 058% (P Å .009 vs. placebo) and 066% (P Å .0009 vs. placebo), respectively. In these groups, about mg dose groups were proportional to dose on study days 1 and 14 (table 3) . However, on day 14, the mean C max for the 500-one-half of subjects had free and total carnitine levels that fell (6) ery values at the 250-mg and 500-mg dose levels approximated
the bioavailability values determined from the serum data.
Transaminase elevation 1 (0) 0 5 (1) 4 (1) NOTE. Nos. in parentheses are no. of subjects experiencing grade II event.
Discussion
In this study, adefovir dipivoxil was administered for 14 consecutive days at doses of either 125, 250, or 500 mg to mg dose group was 24% lower than on day 1 (P Å .02). Serum AUC values could not be calculated for subjects in the 125-people with HIV infection. Anti-HIV activity was demonstrated after 14 days of adefovir dipivoxil administration, based on mg dose group because there were too few detectable serum adefovir levels at the time points sampled. For the 2 highest significant decreases in p24 antigen and plasma viral RNA concentrations in the drug-treated groups. At the dosing regidose groups, mean AUC values were approximately dose-proportional on both day 1 and day 14 of the study (table 3) .
mens studied, a dose-dependent reduction in virus load was not seen. Although the magnitude of reduction in p24 antigen When the mean AUC values were compared between day 1 and day 14 for the 500-mg group, a small (8%) but statistically concentration (median: 25% -31%) after 14 days of adefovir dipivoxil treatment was less than that reported for 14 days significant decrease was seen (P Å .04). Bioavailability values (determined by comparison to intravenous adefovir data) also of zidovudine monotherapy (mean reduction: 60%) [26] , the reduction seen in viral RNA levels (median: 0.4 -0.6 log 10 U) decreased on day 14 compared with day 1 for the 500-mg dose group only (P Å .005) (table 3). For the 500-mg dose group, is similar [26] . Furthermore, preliminary reports from a study in which subjects received 125 mg of adefovir dipivoxil daily mean T max also increased, from 1.8 h at day 1 to 3.0 h at day 14 (P Å .001). Elimination half-life of adefovir dipivoxil, for 12 weeks show that this magnitude of RNA decrease is sustained over the 12-week period [27] . Ultimately, it will be calculated for the 2 highest dose groups, was Ç5.0 h. / 9d2f$$au38 06-24-97 21:34:00 jinfa UC: J Infect congenital carnitine depletion syndromes (i.e., muscle stores depleted to 1.5% of normal) have been associated with no signs or symptoms in some patients but have been associated with cardiomyopathy, skeletal muscle myopathy, encephalopathy, intolerance of fasting, hypoketotic hypoglycemia, and a Reye's-like syndrome in others [28 -33] . In patients receiving courses of therapy with pivampicillin, serum carnitine levels were reported to be depleted to Ç15% or less of baseline values [18 -20] . In a group of AIDS patients who had been receiving zidovudine for at least 8 weeks, mean free and total carnitine levels were reported as Ç1.0 mmol/dL (20%) lower than the mean level for the control (HIV-negative) group [34] . Decreased muscle carnitine has also been reported in patients with zidovudine-induced mitochondrial myopathy [35] . After receiving 14 days of 125 mg of adefovir dipivoxil daily, no subject in this study had a free or total serum carnitine level that fell below the normal range, although this dose group showed a median decrease of 12% in free carnitine. In the 2 higher dose groups, the decrease in serum carnitine (median, 58% -66%) was greater than in the 125-mg group but was less than that reported following courses of pivampicillin therapy [18] . It will be important to see if a further decrease occurs during longer periods of adefovir dipivoxil administration at any dose level.
At the dose regimens studied, adefovir dipivoxil generally showed dose-proportional increases in adefovir C max and AUC Table 3 . Mean adefovir dipivoxil pharmacokinetic parameters on study days 1 and 14. 
